Drug Type ASO |
Synonyms IOC 001, IOC001 |
Target |
Action antagonists |
Mechanism IGF-1R antagonists(Insulin-like growth factor I receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | United States | 07 Nov 2022 | |
Ovarian Cancer | Preclinical | United States | 07 Nov 2022 | |
Transitional Cell Carcinoma | Preclinical | United States | 07 Nov 2022 |